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Antibody therapy may be an alternative treatment option for infections caused by the multi-
drug resistant (MDR) bacterium Acinetobacter baumannii. As A. baumannii has multiple
capsular serotypes, a universal antibody therapy would need to target conserved protein
antigens rather than the capsular polysaccharides. We have immunized mice with single or
multiple A. baumannii strains to induce antibody responses to protein antigens, and then
assessed whether these responses provide cross-protection against a collection of
genetically diverse clinical A. baumannii isolates. Immunized mice developed antibody
responses to multiple protein antigens. Flow cytometry IgG binding assays and
immunoblots demonstrated improved recognition of both homologous and heterologous
clinical strains in sera from mice immunized with multiple strains compared to a single strain.
The capsule partially inhibited bacterial recognition by IgG and the promotion of phagocytosis
by human neutrophils. However, after immunization with multiple strains, serum antibodies to
protein antigens promoted neutrophil phagocytosis of heterologous A. baumannii strains. In
an infection model, mice immunized with multiple strains had lower bacterial counts in the
spleen and liver following challenge with a heterologous strain. These data demonstrate that
antibodies targeting protein antigens can improve immune recognition and protection against
diverse A. baumannii strains, providing support for their use as an antibody therapy.
Keywords: A. baumannii, antibodies, growth inhibition, neutrophils, heterologous protectionINTRODUCTION
Antibiotic resistant Acinetobacter baumannii infections have spread rapidly across hospitals,
particularly intensive care units, increasingly causing nosocomial infections that are associated
with a mortality rate that can be greater than 50% (1–5). Clinical isolates of A. baumannii are often
highly resistant to multiple antibiotics, including carbapenems, making them difficult to treat (5).org July 2021 | Volume 12 | Article 7055331
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to overcome the antimicrobial resistance (AMR) profiles, but
extremely multidrug resistant isolates with limited treatment
options are now being identified in patients (6). This is
compounded as currently, there are no licensed vaccines to
counteract the growing threat of A. baumannii infections. As a
consequence, A. baumannii is the top priority pathogen in recent
WHO reports on AMR, and developing alternative methods of
treating or preventing A. baumannii infections is a global
imperative (1). A. baumannii seems to be a particularly prevalent
pathogen in Asian countries: For example, in Thailand, infections
with multi-drug resistant A. baumannii were the dominant
cause of death due to AMR infections in 2010, estimated to
cause over 25,000 deaths (7).
A potential adjunct treatment option for severe A. baumannii
infections is monoclonal antibody therapy that specifically targets
surface A. baumannii antigens, thereby improving immune
recognition and clearance of the bacteria by the host (6, 8). Proof
of principle studies have shown that whole A. baumannii cell
preparations inactivated using either formalin (9, 10), antibiotic
treatment (11), lipopolysaccharide removal (12), or by targeted
gene deletion (13), induce antibody responses to A. baumannii
that are partially protective against subsequent infections in mice
with the homologous strain. Similarly, outer membrane complexes
(OMCs) (14, 15), vesicles (OMVs) (16) and at least fifteen
recombinant proteins (17–33) have been shown to elicit partially
protective anti-A. baumannii antibody responses. However, the
extensive genetic and antigenic heterogeneity in A. baumannii
strains poses a significant challenge in the development of cross-
protective antibody responses. Although anti-capsular antibody
protects against A. baumannii infections in both mice (34) and rat
(35) infectionmodels, over 100 unique capsule loci (KL types) have
been described for A. baumannii clinical strains (36). For example,
a recent evaluation of 191 isolates collected from three tertiary
hospitals in Thailand reported high capsule type diversity with a
total of 24 KL types identified, and the three KL types with the
highest prevalenceKL10, KL6 andKL47only accounting for 15.7%,
15.2% and 11.0% of the isolates evaluated respectively (37). This
diversity inhibits usingA. baumannii capsular antigen as the target
for a monoclonal antibody therapy. Targeting conserved sub-
capsular antigens offer an attractive alternative to targeting the
capsular antigen. However, the relatively low abundance of protein
antigens compared to capsular antigen and their sub-capsular
localization suggests antibody to protein antigens are likely to be
less protective than antibody to capsule (38). Furthermore, due to
the extensive genetic diversity amongst A. baumannii strains, only
approximately 2,000 genes are common to almost all strains,
representing a minority of the over 20,000+ genes found in the A.
baumanniipan-genome (39).Furthermore,onlya small proportion
of the core genes are predicted to be expressed on the surface of
bacterial cells and therefore potentially accessible to therapeutic
antibodies. Despite these problems, antibodies raised by
vaccinating with either whole cells (9, 13, 14) or protein antigens
(17, 20, 21, 29, 30, 40) have been shown to recognize and protect
against infection with heterologous A. baumannii strains,
indicating an anti-protein approach is feasible. However, the KLFrontiers in Immunology | www.frontiersin.org 2types and degree of genomic diversity between the strains used in
these studies was unclear making the clinical potential of the
demonstrated cross-protective immunity hard to assess.
Here we have investigated whether antibody responses
developed in response to exposure to live A. baumannii are
able to recognize heterologous strains, including those with a
different KL type. To assess cross-reactivity between antisera and
clinically relevant strains, we have tested mouse antisera raised
against a single A. baumannii strain or three different strains
against nine Thai clinical A. baumannii isolates. As antibody
mediated immunity to bacterial pathogens can be mediated by
improving bacterial agglutination, membrane attack complex
(MAC)-dependent bacterial lysis or complement- or Fcg
receptor-dependent phagocytosis, we have used in vitro assays
to evaluate these functions in different antisera. The protective
efficacy of immunization with a selected combination of strains
was tested in a mouse model of infection. Our hypothesis was
that when compared to immunization with a single strain,
sequential immunization with different clinical isolates would
select for antibody responses to immunogenic, conserved A.
baumannii protein antigens and thereby induce improved
cross-protective antibody responses.MATERIALS AND METHODS
Bacterial Strains and Culture Conditions
The nine clinicalA. baumannii isolateswere obtained frompatients
admitted to Songklanagarind and Siriraj Hospitals, Thailand (37)
(Table 1). AB5075wild-type andunencapsulatedAB5075Dwzawere
obtained from theManoil labA.baumanniimutant library (https://
www.gs.washington.edu/labs/manoil/baumanniii.htm). Bacteria
were cultured at 37°C on LB plates or in LB broth to an optical
density at 600nm of 0.8 (approximately 109 CFU/ml) and stored
at -80°C in 10% glycerol as single use aliquots.
Bacteremia Mouse Model of
A. baumannii Infection
All in vivo experiments using mice were performed according to
United Kingdom national guidelines for animal use and care.
Experiments performed at UCL were approved by the UCL
Biological Services Ethical Committee and the UK Home
Office (P64714548). Experiments used 5–6-week-old outbred
female CD1 mice obtained from Charles River Laboratories. A.
baumannii associated bacteremia mouse model was established
by the intraperitoneal route by testing bacterial doses ranging
from 106 to 1010 CFU/mouse in the presence or absence of
varying concentration of mucin. There was rapid clearance of
bacteria at all doses when injected in the absence of mucin. A
minimum lethal dose of 1.0 x 109 CFU/mouse was determined
for the AB1 strain. With this dose, significant target organ CFU
could be recovered consistently at 24 hours post-inoculation.
Mice rapidly developed fatal infection at later time points. To
evaluate the protective efficacy of the AB3879 and multi strain
antisera, the AB1 stock was washed and resuspended in
appropriate volume of 5% Mucin in PBS to inject a dose ofJuly 2021 | Volume 12 | Article 705533
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Mucin/PBS served as a control. At 24 hours post infection, mice
were sacrificed, and the lungs, liver and spleen harvested,
homogenized and the bacterial counts obtained by plating
serial dilutions on LB agar plates.
Anti-A. baumannii Mouse Sera
The majority of experiments were performed using pooled serum
obtained from mice immunized with live sub-lethal doses (106
CFU/mouse/vaccination) of A. baumannii via the intraperitoneal
route. Homologous sera namely anti-AB3879, anti-AB5075WT and
anti-AB5075Dwza were generated following three immunizations,
14 days apart with the same A. baumannii isolate. Multi strain
antisera was generated by sequential immunization with AB3879,
AB1492-09 and AB1615-09 isolates respectively. Sera from non-
immunized mice were used as controls.
Whole Cell ELISA
Antibodies specific to antigens in different A. baumannii strains
were measured by whole cell ELISA. Briefly, A. baumannii were
grown to late log-phase (OD600nm = 0.8, approximately 10
9 CFU/
ml), washed, and resuspended in PBS. 96-well plates (Brand plates,
IMMUNOGrade) were coated with 50 µl of this bacterial
suspension, overnight at 4°C, inactivated using 50 µl of 4%
paraformaldehyde for 10 minutes, then blocked with 5% non-fat
milk/0.05% Tween 20/PBS (blocking buffer) for 3 hours at room
temperature. Sera were diluted to a 1:100 dilution in blocking
buffer before addition, and binding to bacterial antigens detected
with goat anti-mouse IgG conjugated to Horse-radish peroxidase
(Invitrogen) and detected using the TMB substrate.
Immunoblot Detection of Bacterial Lysate
Recognition by IgG
A. baumannii bacterial lysate were obtained by resuspending
bacteria in 1X lithium dodecyl sulfate (LDS) sample buffer
(NuPAGE LDS Sample buffer (4X), Invitrogen) with 50mM
dithiothreitol [NuPAGE sample reducing agent (10X)], boiled
at 95°C for 10 min, separated on a gradient 4-12% SDS-
polyacrylamide gel (NuPAGE Bis-Tris gels), and transferred to
nitrocellulose membranes using the iBlot 2 Dry Blotting SystemFrontiers in Immunology | www.frontiersin.org 3(ThermoFisher Scientific). Nitrocellulose membranes were
blocked with 10% non-fat milk/0.05% Tween 20/PBS (blocking
buffer) for 2 hours then incubated with mouse sera at a 1:1000
dilution overnight at 4°C, washed and then probed using an anti-
mouse IgG conjugated with horseradish peroxidase. Protein
bands were visualized using the chemiluminescent ECL reagent
(Amersham) on the ImageQuant™ LAS 4000.
Flow-Cytometry Detection of Bacterial
Surface Recognition by IgG
Total IgG binding to A. baumannii was assessed using flow
cytometry. 106 CFU of A. baumannii was incubated with mouse
antisera in triplicate for 1 hour at 37°C, followedby goat anti-mouse
IgG-allophycocyanin (APC) (Invitrogen) for 1 hour at room
temperature. Samples were analyzed using a BD FACSVerse and
data processed using FlowJo software for Windows (version 10).
Markers for identifying IgG positive bacteria was set using bacteria
incubated with PBS and then incubated with the secondary
antibody. The proportion of IgG positive bacteria was gated on
the single-cell population of unstained and bacteria labelled with
secondary antibody only. Two independent experiments were
conducted using stocks cultured on separate days and stored as
single-use aliquots. A positive correlation between the two
independent experiments was observed (Spearman correlation:
R=0.7157, p-value=0.0359).
Genomic Analysis of the Capsule Locus
Capsule KL loci were previously determined using Kaptive and
an A. baumannii KL database (37, 41).
Growth Inhibition Assays
102 CFU of A. baumannii was incubated with 1:100 dilution of
mouse antisera in triplicate and bacterial growth (OD600nm) at
37°C in 5% C02 was monitored every hour over a 24-hour period
using the Spark multimode microplate reader (TECAN).
Neutrophil Opsonophagocytosis Assays
Phagocytosis was investigated using an established flow cytometry
assay (42), neutrophils extracted from fresh human blood from
healthy adult donors and fluorescent A. baumannii labeled withTABLE 1 | A. baumannii isolate information.
Strains KL class MLST type Biological sample source Hospital/Source
AB15g KL47 ST2 Sputum Siriraj Hospital, Bangkok
AB98 KL47 ST215 Unknown Siriraj Hospital, Bangkok
AB1615-09 KL47 ST164 Sputum Songklanagarind Hospital, Songkhla
AB56 KL10 ST2 Unknown Siriraj Hospital, Bangkok
AB3879g KL10 ST215 Sputum Songklanagarind Hospital, Songkhla
AB1g KL52 ST2 Pus Siriraj Hospital, Bangkok
NPRC-AB20 KL52 ST215 Unknown Songklanagarind Hospital, Songkhla
AB55 KL6 ST2 Unknown Siriraj Hospital, Bangkok
AB1492-09 KL2 ST2 Sputum Songklanagarind Hospital, Songkhla
AB5075WT KL25 ST1 n/a Manoil lab A. baumannii mutant library
AB5075Dwza n/a ST1 n/a Manoil lab A. baumannii mutant libraryJuThe nine Thai strains used in this study were isolated from patients across either the Siriraj or Songklanagarind hospitals in Thailand. The AB5075WT and AB5075Dwza strains lab isolates
were obtained from the Manoil lab.
gStrains were determined to be resistant to multiple classes of antibiotics that include a fluoroquinolone (n = 1), aminoglycosides (n = 2), a tetracycline (n = 1) and b-lactam antibiotics
including carbapenems (n = 9). All three strains were sensitive to colistin (37).ly 2021 | Volume 12 | Article 705533
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Probes). Bacteria was opsonized with mouse antisera and 5%
heat-inactivated human sera for 30 minutes at 37°C followed by
the addition of 105 neutrophils to a final multiplicity of infection
(MOI) of approximately 1:100. A minimum of 5000 cells were
analyzed by flowcytometry using a BD FACSVerse and data
processed using FlowJo software for Windows (version 10). To
identify the percentage of neutrophils associated with bacteria,
neutrophils that had not been incubated with bacteria were used
to identify the negative control. The proportion of bacteria positive
neutrophils was gated on the single-cell population of neutrophils
not incubated with bacteria. To combine the percentage of bacteria
associated neutrophils and the intensity of association, a
fluorescence index was determined by multiplying the percentage
of positive neutrophils by the geometricmedian fluorescence of the
positive population. All sera were tested in parallel on the same day,
at the same concentration with the same batch of bacteria and
neutrophils for each independent experiment.
Bacterial Cell Size Measurement
A. baumannii strainswere cultured in LBbroth to anOD600nm of 0.4,
pelleted and resuspended in 300 µL sterile PBS. 10 µL bacteria
solution was mixed with 2 µL 2000 kDa FITC-Dextran (Sigma) at
10 mg/ml before spotting 10 µL onto a glass microscope slide and
sealed with a coverslip. Slides were imaged using a Zeiss LSM 880
confocal microscope with Plan-Apochromat 63x/1.4 Oil DIC M27
using standard confocal mode driven by ZEN Black 2.3 software
(Carl Zeiss). A minimum of 1,000 individual bacteria were imaged
using a 490 nm laser with collection of light at 520 nm. Tomeasure
bacterial cell length, ImageJ 1.53a software was used to first convert
images to 8-bit with auto-threshold, before identifying singlet
bacterial particles within a defined circularity and size range.
Statistical Analysis
Statistical analyses were conducted using GraphPad Prism version 8
(GraphPad, USA). Data are presented as means, and the error bars
represent standard deviations. Parametric data were analyzed using
Student’s T test and nonparametric data using the Mann-Whitney
U test. Doubling times from growth curves were calculated using the
log of exponential growth equation in GraphPad version 8 (https://
www.graphpad.com/guides/prism/latest/curve-fitting/reg_log-of-
exponential-growth.html). The optical density values obtained
from bacterial growth at the exponential phase (6-16 hours) were
log transformed and the non-linear regression of exponential
growth with a log population equation used to calculate doubling
time in the presence of respective anti-A. baumannii sera. The
doubling time ratio was calculated by dividing doubling time in
respective sera over doubling time in sera from non-immunized
mice (DT sera/DT control).
RESULTS
Immunization With A. baumannii Induces
Antibody Responses That Recognize
Multiple Conserved Proteins
Nine A. baumannii strains were isolated in 2016 from clinical
specimens obtained from two tertiary hospitals in Thailand,Frontiers in Immunology | www.frontiersin.org 4Siriraj Hospital, Bangkok and Songklanagarind Hospital,
Songklanagarind Hospital, Hat Yai, Songkhla Province. These
strains subsequently underwent whole-genome sequencing and
sequence typing (37). The nine isolates tested had a range of
multilocus sequence typing (MLST) sequence types (ST) and KL
types including five ST2 (representing global clone 2), three
ST215 and one ST164 strains and three KL47, two KL10, two
KL52, one KL6 and one KL2 capsular loci strains (Table 1). None
of the isolates share both the capsule loci and MLST (Institute
Pasteur Scheme) type. Two additional strains, the AB5075 (ST2,
KL25) wild-type and the unencapsulated AB5075Dwza (strain
name: tnab1_kr121203p06q153, genotype: wza-153::T26) strain
were obtained from the Manoil lab A. baumannii mutant library
(https://www.gs.washington.edu/labs/manoil/baumanniii.htm).
Groups of mice were immunized with either AB3879 (KL10
type) or sequentially with the AB3879, AB1492-09 (KL2) then
AB1615-09 (KL47) strains (multi strain group) with both groups
receiving the same total bacterial CFU. Sera was obtained 2
weeks after the third injection, pooled and used for whole cell
ELISAs and to probe immunoblots of all nine A. baumannii
strains. Whole cell ELISAs showed both antisera recognized all
nine strains to varying degrees, with higher antibody levels to all
strains observed with the multi strain antisera (Figures 1A, B).
The immunoblots showed both antisera recognized multiple
bands of similar size for all the probed A. baumannii strains
(Figures 1C, D). More immunoreactive bands were visible in
immunoblots probed with multi strain antisera (Figure 1D,
black arrows), although one band above 70 KDa was weaker
compared to the results for lysates probed with AB3879 antisera
(Figure 1C, black arrow). These data demonstrate that mouse
antisera generated by inoculation of live A. baumannii can
recognize different A. baumannii strains expressing different
KL types and from different STs, and that at least some of the
antibody responses target multiple protein antigens that are
likely to be conserved between A. baumannii strains.The Effects of the Capsule on Antibody
Binding to A. baumannii in Sera From
Immunized Mice
Previous authors have demonstrated that the A. baumannii
polysaccharide capsule inhibits access of antibody to
underlying protein antigens (18). In addition, antisera raised in
mice to the wild-type A. baumannii strains is also likely to
contain a mixture of IgG to capsular and protein antigens.
To assess whether the A. baumannii capsule was a target
antigen to IgG in the antisera and/or inhibited anti-protein
antigen recognition, we used a flow cytometry IgG binding
assay to measure IgG deposition on live A. baumannii
incubated in antisera. Initially, we measured IgG deposition on
the AB5075 wild-type (KL25, ST1) and unencapsulated
AB5075Dwza strains using antisera raised by immunizing mice
with either of these two strains. This confirmed that mouse
antisera raised against encapsulated A. baumannii contained IgG
that recognized the capsule, with increased IgG deposition on the
AB5075 wild-type strain when incubated in antisera raised
against the encapsulated AB5075 wild-type compared to theJuly 2021 | Volume 12 | Article 705533
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The results also indicated there was significant IgG in both
AB5075WT and AB5075Dwza antisera against protein antigens,
with marked IgG deposition occurring on the AB5075Dwza
unencapsulated strains (Figure 2A, right panel and B). When
incubated in antisera raised against the AB5075Dwza
unencapsulated strain, there was reduced IgG deposition on
the AB5075 strain compared to the AB5075Dwza strain
demonstrating the capsule impaired recognition of A.
baumannii by IgG to protein antigens (Figure 2A, 2nd row).
When incubated in AB3879 and multi strain antisera there wereFrontiers in Immunology | www.frontiersin.org 5high levels of IgG binding to the unencapsulated AB5075Dwza
strains, confirming these sera contained a significant anti-protein
antigen IgG response (Figures 2A, B). However, there was
markedly reduced IgG binding to the encapsulated AB5075
wild-type strain in AB3879 and multi strain antisera,
confirming the capsule impaired recognition of protein
antigens. There was a small degree of residual IgG binding to
the encapsulated AB5075 wild-type strain in the multi strain
antisera, demonstrating that some recognition mediated by
antiprotein IgG occurred in this serum even against an
encapsulated strain.A B
DC
FIGURE 1 | Whole cell ELISA and immunoblot detection of the reactivity of mouse antisera with A. baumannii isolates. Whole cell ELISAs of IgG binding to nine A.
baumannii isolates using either AB3879 (A) or multi strain antisera (B). Whole cell lysates from the nine diverse A. baumannii isolates were resolved on a reduced 4-
12% gradient gel, probed with mouse antisera and anti-mouse IgG-HRP. Each lane represents a clinical A. baumannii isolate indicated above. Immunoreactive
proteins detected when blot was probed with either AB3879 (C) or multi strain antisera (D). Black arrows represent bands unique to immunoblots probed with either
AB3879 or multi strain sera. Bars represent mean values for each group and the error bars indicate standard deviations (SDs) (n = 3). Representative data from two
independent experiments is shown.July 2021 | Volume 12 | Article 705533
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B
FIGURE 2 | Flow cytometry detection of IgG binding to wild type and un-encapsulated AB5075 isolates by mouse antisera. Representative histograms showing the
recognition of 1x106 CFU of AB5075 wild-type strain (left panel) and un-encapsulated AB5075Dwza strain (right panel) to either (A) AB5075WT, AB5075Dwza, AB3879
or multi strain antisera. (B) Bar graph presenting the proportion of AB5075WT and AB5075Dwza bacteria bound by IgG in AB3879, multi strain, AB5075WT or
AB5075Dwza antisera. The Y axis shows the fluorescence index calculated by multiplying the percentage of IgG positive bacteria to the median fluorescent intensity of
the positive population that was detected in each isolate. Bars represent mean values for each condition/strain and the error bars indicate standard deviations (SDs)
(n = 3). T-test was used for statistical analysis ***p-value < 0.001, ****p-value =< 0.0001. Representative data from two independent experiments is shown.Frontiers in Immunology | www.frontiersin.org July 2021 | Volume 12 | Article 7055336
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Strains Incubated in Antisera From
Immunized Mice
To further characterize whether capsular and/or protein antigens
were targets for IgG in the AB3879 andmulti strain antisera, the IgG
deposition assay was repeated with all nine Thai clinical isolates. For
the AB3879 antisera, the highest levels of IgG binding occurred to
the homologous AB3879 strain, and to strain AB56 that shares the
same capsule locus (KL10) (Figures 3A, C). In addition, after
incubation in AB3879 antisera, there was significant IgG binding
to two of the KL47 capsule strains (AB98 and AB1615-09), one of
which shared the same ST type to AB3879 (ST215). There was
minimal IgG binding to the remaining strains (Figures 3A, C).
These data show that although the sera to AB3879 contains
antibodies to multiple conserved protein antigens, IgG deposition
in this antiserum correlated with strain KL type except for the KL47
strains. Genomic analysis of the capsule loci of the Thai clinical
isolates showed significant differences between the KL47 and KL10
capsule loci, suggesting that preservation of capsule structure
between these KL types is unlikely to explain the cross-reactivity
observed (Figure 4).
In contrast to the data for AB3879 antisera, incubation in
multi strain antisera (raised against KL10, KL2 and KL47 strains)
resulted in IgG binding to eight of the nine strains investigated
(Figures 3B, C). The highest binding was to AB3879 (KL10) and
AB1615-09 (KL47) strains included in the vaccination schedule,
as well as the KL10 strain, AB56 (similar to the results for
AB3878 antisera), to two other KL47 strains and the AB1492-09
(KL2) strain (included in the vaccination schedule). In addition,
there were also lower levels of IgG binding detectable to the
heterologous strains AB1 (KL52) and AB55 (KL6) (Figures 3B,
C) indicating that anti-protein responses in multi strain antisera
allows immune recognition of a wider range of strains than in the
AB3879 antisera.




Agglutination by specific antisera can inhibit bacterial growth in
broth culture (43). To evaluate whether anti-capsular and/or
anti-protein antibodies could inhibit A. baumannii growth, we
used antisera raised against the encapsulated AB5075 wild-type
and the unencapsulated AB5075Dwza strain to measure growth
inhibition in both AB5075WT and AB5075Dwza strains. Growth of
the encapsulated AB5075 wild-type strain was inhibited by
antisera raised against the encapsulated AB5075 strain but not
by antisera raised against the unencapsulated AB5075Dwza or
AB3879 or the multi strain antisera (Figure 5). Reduced growth
of the unencapsulated AB5075Dwza strain was only observed
when approaching the stationary phase after incubation with
antisera raised against AB5075WT, AB5075Dwza and the multi
strain group (Supplementary Figure 1), suggesting late phase
growth could be inhibited to a small degree by anti-protein
antibodies. These data indicate growth inhibition was largely
dependent on capsule specific antibodies.Frontiers in Immunology | www.frontiersin.org 7Growth Inhibitory Activity of AB3879 and
Multi Strain Antisera Against Thai A.
baumannii Strains
To further characterize the inhibitory activity in the AB3879 and
multi strain antisera, the growth inhibition assay was repeated
with all nine Thai clinical isolates. When compared to sera from
non-immunized mice, AB3879 antisera inhibited the growth of
both KL10 strains AB3879 and (to a lesser extent) AB56, with an
increased doubling time and significantly reduced the total CFU
reached in culture for both strains (Figure 6 and Table 2). Multi
strain antisera (raised against KL10, KL2 and KL47 type strains)
inhibited growth and increased the doubling times for all five
KL10 or KL47 strains, and significantly reduced the total CFU
reached for the AB98 (KL47), AB1615-09 (KL47) and AB3879
(KL10) strains (Figure 6 and Table 2). Overall, all the strains
showing significant growth inhibition in A. baumannii antisera
were the homologous KL types to strains used to generate the
antisera and showed high levels of IgG binding in the flow
cytometry assay (Figure 3), suggesting this effect was largely
dependent on anti-capsular antibodies. However, growth was not
inhibited in antisera for every strain showing high levels of IgG
binding (e.g., AB98 and AB1615-09 in AB3879 antisera) or for all
KL types used to generate the antisera (e.g., the KL2 strain
AB1492-09 in multi strain antisera) (Supplementary Figure 2).
The Effects of the Capsule on Promotion
of A. baumannii Neutrophil Phagocytosis
by Antisera
To assess whether the A. baumannii capsule inhibited neutrophil
phagocytosis following opsonization with antisera, we measured
phagocytosis using a flow cytometry assay of the encapsulated
AB5075 wild-type and the unencapsulated AB5075Dwza strains
using antisera raised by immunizing mice with either of these
two strains. As expected, the encapsulated AB5075 strain was
considerably less susceptible to neutrophil phagocytosis
compared to the unencapsulated AB5075Dwza strain following
opsonization with all antibodies, including sera from non-
immunized mice (Figure 7). Although IgG deposition on the
AB5075 wild-type strain was observed with antisera raised
against AB5075WT, AB5075Dwza and the multi strain group
(Figure 2), only incubation in AB5075WT and to a lesser extent
multi strain antiserum, increased neutrophil phagocytosis of this
strain (Figures 7A,B). In contrast, the unencapsulatedAB5075Dwza
strain showed significant increases in susceptibility to neutrophil
phagocytosis following opsonization with all antisera tested.
Cumulatively, these data confirm the A. baumannii capsule
inhibits promotion of neutrophil phagocytosis by antisera, but
despite this, anti-protein antibodies in the multi strain antisera
can promote a modest improvement of the phagocytosis of a
heterologous encapsulated strain.
Effects of Incubation in Antisera on
Phagocytosis of Thai A. baumannii Strains
To further characterize the ability of AB3879 and multi strain
antisera, to promote neutrophil phagocytosis of A. baumannii
strains, we repeated the flow cytometry neutrophil phagocytosisJuly 2021 | Volume 12 | Article 705533
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neutrophil phagocytosis when incubated in naïve mouse sera
varied markedly between A. baumannii strains even within KL
type (e.g., KL47 and KL52 strains) (Figure 8). Compared to
control sera, the AB3879 antisera enhanced phagocytosis of the
homologous AB3879 (KL10) strain to the highest degree, while
multi strain sera also enhanced phagocytosis of the homologous
AB3879 (KL10) and AB1615-09 (KL47) strains to the highestFrontiers in Immunology | www.frontiersin.org 8degree. Higher levels of phagocytosis of the heterologous AB56
(KL10) and AB1 (KL52) strains were also detected when
incubated in either antisera, and for the NPRC-AB20 (KL52)
strain as well in AB3879 antisera (Figure 8A). Overall, the
neutrophil uptake data showed three broad patterns of results.
The first pattern consisted of strains that were susceptible to
neutrophil phagocytosis and in which antisera had little
additional effect (e.g., strains AB15, AB98, and AB1492-09).A
B
C
FIGURE 3 | IgG recognition of a panel of nine A. baumannii isolates by mouse antisera generated against immunization with one strain or sequentially with three
strains. (A) Mouse AB3879 antisera and (B) multi strain (AB3879+AB1492-09+AB1615-09) antisera IgG binding to the surface of A. baumannii isolates as
measured by flow cytometry. The nine isolates are grouped in order of their respective capsule serotypes and are indicated in brackets on the X-axis. Round, square
and triangle isolates belong to the ST2, ST215 and ST164 MLST type respectively. The Y axis shows the proportion of IgG positive bacteria multiplied by the median
fluorescent intensity (MFI) of IgG positive population, in each of the nine A. baumannii isolates. (C) Representative histograms showing IgG binding of 1x106 CFU of
the nine A. baumannii isolates to either AB3897 antisera (left panel) or multi strain antisera (right panel). Grey histogram represents bacteria labelled with 2nd antibody
only, black-dotted line represents bacteria incubated with sera from non-immunized mice and black solid line represents bacteria incubated with the respective sera
(AB3879 antisera left panel and multi strain antisera right panel). The nine isolates and their respective KL class denoting the capsule serotypes are indicated
alongside respective histograms. Dot plots represent triplicate values with lines indicating the mean values and the error bars indicate standard deviations (SDs)
(n = 3). Representative data from two independent experiments is shown.July 2021 | Volume 12 | Article 705533
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FIGURE 5 | Growth inhibitory activity of wild type AB5075 isolates by mouse antisera. 102 CFU of encapsulated AB5075WTstrain was incubated with either,
AB5075WT antisera (black line, solid diamond), AB5075Dwza antisera (black line, open diamond) and sera from non-immunized mice (grey line, solid circle) (A) or
AB3879 antisera (black line, solid square), multi strain antisera (black line, open square), and sera from non-immunized mice (grey line, solid circle) (B). Numbers on
the top left corner represent the ratios of doubling time for respective antisera. Ratios of doubling time in test sera/control sera were calculated with a ratio of > 1.2
indicating delayed growth in the antisera. Line graphs indicate the mean value, and the error bars indicate standard deviations (SDs) (n=6).FIGURE 4 | Organization of the five KL loci represented in the A. baumannii strains. A comparison of the CPS biosynthesis genes clusters and their organization in
the five KL loci represented in the A. baumannii strains. CPS export genes are in black, genes in dark blue are involved in the synthesis of common sugar substrates,
genes in green are involved in the synthesis of complex sugars, genes in yellow encode glycosyltransferases, genes in red encode initiating transferases and genes in
brown encode Acyl or acetyl transferases.Frontiers in Immunology | www.frontiersin.org July 2021 | Volume 12 | Article 7055339
Kamuyu et al. Antibodies to Heterologous A. baumannii StrainsFIGURE 6 | Growth inhibitory activity on a panel of five A. baumannii isolates by mouse antisera. 102 CFU of a panel of A. baumannii isolates were incubated in triplicate
with either AB3879 antisera (left panel) or multi strain antisera (right panel) and the OD600nm measured every 30 minutes for 24 hours. Sera from non-immunized mice was
included as a control (open symbols). Solid symbols represent respective anti-A. baumannii antisera. The five isolates are grouped by their capsule serotype and indicated at
the top of each graph in brackets. Round, square and triangle symbols represent ST2, ST215, and ST164 MSLT types respectively. Numbers on the top left-hand corner
represent the ratios of doubling time for respective antisera. Ratios of doubling time in test sera/control sera were calculated with a ratio of > 1.2 indicating delayed growth in
the antisera. Line graphs indicate the mean value, and the error bars indicate standard deviations (SDs) (n = 6).Frontiers in Immunology | www.frontiersin.org July 2021 | Volume 12 | Article 70553310
Kamuyu et al. Antibodies to Heterologous A. baumannii StrainsThe second pattern were strains that were relatively resistant to
neutrophil phagocytosis in naïve sera for which addition of
antisera significantly improved phagocytosis (e.g., AB1615-09,
AB56, AB3879, AB1, and NPRC-AB20). Importantly, these
included strains in which phagocytosis was increased by A.
baumannii antisera that was raised against heterologous KL
types (e.g., AB1 and NPRC-AB20), demonstrating a potential
effect of anti-protein rather than anti-capsular antibodies. The
last pattern identified was a single strain that was highly resistant
to neutrophil phagocytosis under all conditions (AB55).
We observed that the A. baumannii capsule inhibited
promotion of phagocytosis and the unencapsulated
AB5075Dwza strain was significantly more susceptible to
neutrophil phagocytosis compared to encapsulated AB5075WT
strain, even in naïve sera (Figure 7). To further investigate the
marked difference in susceptibility to neutrophil phagocytosis
observed in the Thai clinical strains, we compared the bacterial
cell length, as a proxy measure of capsule thickness, between the
strains that showed low or no susceptibility to phagocytosis in
naïve sera (AB1615-09, AB56, AB3879, NPRC-AB20 and AB55)
and those strains that were highly susceptible to phagocytosis in
naïve sera (AB15, AB98, AB1 and AB1492-09). No differences
were observed suggesting that the capsule size between these two
groups is unlikely to explain the difference in neutrophil
phagocytosis (Figure 8C).
Sequential Immunization Partially Protects
Against Bacteremia in Mouse Models of
Heterologous A. baumannii Infection
We assessed whether the increased bacterial IgG binding and
neutrophil phagocytosis observed in vitro with the multi strain
antisera toheterologous strains, resulted in increasedprotection ina
mouse model of A. baumannii bacteremia. Groups of 6 mice were
immunized three times with either the single strains AB3879
(KL10) or AB1 (KL52) or sequentially with AB3879, AB1492-09
and AB1615-09 (identical to multi strain antisera group) and then
challengedwith theAB1 strain (Figures 9A).Mice immunizedwith
the homologous strainAB1had significantly lower bacterial CFU in
the spleen, liver, lungs, and kidneys compared to control group
(Figures 9B–E). Similarfindingswere observed inmice immunizedFrontiers in Immunology | www.frontiersin.org 11with AB3879 followed by challenge with the homologous strain
(Supplementary Figure 3), confirming homologous vaccination
protected against subsequent infection.
In contrast, the bacterial burden of mice immunized with the
AB3879 strain and challenged with the AB1 strain, did not differ
from the control group in all organs tested (Figures 9B–E).
However, mice immunized sequentially with three strains, all
heterologous to the AB1 challenge strain, also had reduced
bacterial CFU in the spleen and liver compared to control
group (Figures 9B, C). These data demonstrate that sequential
pre-exposure to heterologous A. baumannii strains partially
protected mice from a lethal injection, indicating a protective
effect of anti-protein antibodies in this serum.DISCUSSION
The use of monoclonal antibodies for the treatment of multi-
drug resistant bacteria is currently undergoing evaluation in
clinical trials for multi-antibiotic resistant bacterial pathogens
such as Pseudomonas aeruginosa and methicillin-resistance
Staphylococcus aureus. These monoclonal antibodies target
either the capsular polysaccharide, secreted protein toxins or
surface membrane proteins such as type III secretion systems
involved in host-pathogens interactions (44). Although the A.
baumannii polysaccharide capsule is highly immunogenic and
induces protective antibodies (34, 35, 45), targeting the capsule
faces significant challenges. These include a wide range of
described KL types (capsule serotypes), and limited knowledge
of which of these, are the predominant cause of clinical cases of
A. baumannii infections, which may also vary in different
geographical locations (37, 46). For example, a total of 24
serotypes were identified among a large number of A.
baumannii clinical isolates from Thailand (37). In contrast, a
study from Vietnam found a total of 4 KL serotypes (KL2, KL49,
KL58, and KL32) (46) but these together represented only 15% of
the isolates in the Thai study. Similar contradictory data have
been obtained using antibodies to different A. baumannii
capsular polysaccharides with the K1 specific monoclonal
antibody 13D6 recognizing 13% of the isolates tested (35),TABLE 2 | Total CFU counts to measure the growth inhibitory effects of AB3879 antisera and multi strain antisera.
Strains KL class ST type Viable bacterial CFU¥
antisera control P-value
AB3879 antisera
AB56 KL10 ST2 2.67 ± 1.66 x 108 1.38 ± 1.12 x 109 0.017
AB3879 KL10 ST215 3.33 ± 1.83 x 107 7.20 ± 6.97 x 108 0.002
Multi strain antisera
AB15 KL47 ST2 5.50 ± 7.33 x 108 5.83 ± 4.90 x 108 0.485
AB98 KL47 ST215 3.25 ± 0.69 x 108 5.25 ± 2.40 x 108 0.039
AB1615-09 KL47 ST164 7.75 ± 2.52 x 107 3.87 ± 1.95 x 108 0.015
AB56 KL10 ST2 2.75 ± 1.86 x 108 4.08 ± 0.86 x 108 0.130
AB3879 KL10 ST215 3.83 ± 1.40 x 107 6.95 ± 5.06 x 108 0.002July 2021 | Volume 12 | Article102 CFU of a panel of A. baumannii isolates was incubated in triplicate with either pooled mouse AB3879 or multi strain antisera at a 1:100 dilution. Growth in sera from non-immunized
mice was included as the control. Viable bacterial counts of isolates were determined by CFU counts after 14 hours of incubation. Bold p-values indicate statistically significant differences
in bacterial counts.
¥Pooled data from 2 independent experiments. Each sample tested in triplicate in each experiment (N = 6).705533
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Frontiers in Immunology | www.frontiersin.org 12whereas C8, targeting the HUMC1 capsular polysaccharide, and
anti-KL22 polyclonal sera recognized 60% of the clinical strains
tested (34, 45). This variation in the proportion of strains
recognized by anti-capsular antibody is likely to reflect
differences between geographical sources in the predominant
KL types, and perhaps for the anti-KL22 data, partial cross
recognition of surface proteins found in the capsular material.
These data suggest that a monoclonal therapy targeting A.
baumannii KL types could be ineffective due to KL type
diversity and would also have to be tailored to the KL types
prevalent in each specific geographical region.
Developing monoclonal antibodies that recognize conserved
sub-capsular protein antigens could overcome some of the
challenges faced by targeting the capsular polysaccharide.
Identifying which conserved proteins are potential vaccine
candidates or targets of antibody therapy has been addressed
using reverse vaccinology approaches for many pathogens (47).
However, there are few data on acquired protective immunity to
A. baumannii to aid in protein target antigen identification. To
begin to address this, we have generated anti-A. baumannii sera
by immunization against a single strain or sequential
immunization with 3 strains, an approach that has been
exploited to induce broadly reactive antibody responses in
HIV (48), Influenza (49) and Neisseria meningitidis (50). Our
results demonstrated that polyclonal mouse antisera generated
following immunization with live A. baumannii contained a
mixture of antibodies that target the polysaccharide capsule and
protein targets. KL-type specific anti-capsular IgG responses
predominated but using immunoblots and assays with an
unencapsulated or heterologous KL type strains, we have
identified additional anti-protein antigen responses. Previous
data using sequential vaccination with outer membrane vesicles
from three heterologous N. meningitidis strains improved
antibody responses against genetically diverse strains and
boosted the antibody titers to the highly conserved surface
protein A (NspA) (50). Similarly, our data show that
compared to immunization with a single strain, sequential
immunization with multiple strains elicited antibodies that
recognized more immunoreactive protein bands on
immunoblot, boosted IgG recognition of both homologous and
heterologous isolates, and resulted in enhanced phagocytosis of
some heterologous isolates. Furthermore, prior immunization
with three heterologous strains reduced target organ CFU in
mice challenged with another A. baumannii strain. These data
provide proof of principle that antibody to protein antigens can
provide cross-protective immunity, although the ability of the
capsule to inhibit antisera dependent phagocytosis remains a
significant challenge.
We have used in vitro assays to help clarify mechanisms by
which antisera might protect against A. baumannii. Table 3
summarizes and allows cross-comparisons of the results from
these assays. There was a lack of concordance between the whole-
cell ELISA and immunoblot results, which recognized proteins in
all strains, and the surface IgG binding data which showed
variable reactivity to the same strains. These results suggest
that the flow cytometry assay was dominated by anti-capsular
antibody responses, although it clearly identified an anti-proteinA
B
FIGURE 7 | Neutrophil opsonophagocytosis of wild type and un-
encapsulated AB5075 isolates by mouse antisera. (A) FAMSE labelled
AB5075WT (left panel) and AB5075Dwza (right panel) were opsonized with
either AB5075WT, AB5075Dwza, AB3879 or multi strain antisera and incubated
with healthy human neutrophils at Bacteria: Neutrophil MOI of 100:1. Sera
from non-immunized mice was included as a control. Each graph shows a
grey histogram that represents neutrophils incubated with no sera, black-
dotted line represents neutrophils with bacteria opsonized with sera from
non-immunized mice and black solid line represents neutrophils with bacteria
opsonized with the respective sera indicated on the left. (B) Bar graph
showing fluorescence index calculated by multiplying the percentage of IgG
positive bacteria to the median fluorescent intensity of the positive population
that was detected in each isolate, on the Y axis. The X-axis shows either
AB5075WT (left) or AB5075Dwza (right) opsonized with either AB3879, multi
strain, AB5075WT or AB5075Dwza antisera as indicated in the legend. Bars
represent mean values for each condition/strain tested in triplicate and the
error bars indicate standard deviations (SDs) (n=3). T-test was used for
statistical analysis *p-value < 0.05, ***p-value < 0.001 Representative data
from two independent experiments is shown.July 2021 | Volume 12 | Article 705533
Kamuyu et al. Antibodies to Heterologous A. baumannii Strainsantigen response in some antisera/strain conditions. This was
expected as the flow cytometry assay measures IgG binding to
the surface of the whole bacterium and our data confirms
previous data that the A. baumannii capsule blocks access to
subcapsular protein antigens (18), whereas whole-cell ELISAs
measure antibody responses to all bacterial antigens. However,Frontiers in Immunology | www.frontiersin.org 13there was heterologous recognition of some strains, especially in
sera obtained from mice vaccinated with three different strains
indicating IgG binding to heterologous A. baumannii strains
through anti-protein antibody responses. The functional
consequences of the anti-protein responses were investigated
using growth inhibition in antisera and by flow cytometryA B
C
FIGURE 8 | Opsonophagocytosis by human neutrophils of a panel of nine A. baumannii isolates by mouse antisera generated following immunization with one strain
or sequentially with three strains. Nine FAMSE labelled A. baumannii isolates were opsonized with either AB3879 antisera, multi strain antisera or sera from non-
immunized mice and incubated with healthy human neutrophils at Bacteria: Neutrophil MOI of 100:1. (A) Shows the fluorescence index calculated by multiplying the
proportion (%) of FAMSE+ve neutrophils and the median fluorescence intensity of the positive population [mean (± standard deviation)] on the Y axis and the nine isolates with
their capsule serotypes indicated in brackets are on the X-axis. Phagocytosis indices in bacteria incubated with non-immune sera, anti-AB3879 sera and multi strain sera for
each isolate is represented in the white, grey and dark grey bars respectively. Bars represent mean values for each condition/strain tested in triplicate and the error bars
indicate standard deviations (SDs) (n = 3). T-test was used for statistical analysis *p-value < 0.05, **p-value < 0.001, ***p-value < 0.0001, ns: p-value= not significant.
Representative data from two independent experiments is shown. (B) Representative histograms showing phagocytosis of FAMSE labelled A. baumannii isolates incubated
with either AB3897 antisera (left panel) and multi strain antisera (right panel). Grey histograms represent no sera (neutrophils only), black-dotted line represents addition of
neutrophils to bacteria incubated with sera from non-immunized mice and black solid line represents addition of neutrophils to bacteria incubated with the respective mouse
antisera. The nine isolates and their respective KL class denoting the capsule serotypes are indicated alongside respective histograms. (C) Comparison of the capsule size in
bacterial isolates that show low (N = 5) versus high (N = 4) susceptibility to neutrophils phagocytosis. Box and whisker plots represent mean values for each group and the
error bars indicate the minimum and maximum value. Mann-Whitney U-test was used for statistical analysis *p-value < 0.05, **p-value < 0.01, ns: p-value=not significant.July 2021 | Volume 12 | Article 705533
Kamuyu et al. Antibodies to Heterologous A. baumannii Strainsneutrophil uptake assay. Inhibition of A. baumannii growth
when cultured in broth in the presence of antisera was only
caused by KL type specific anticapsular antibody. Susceptibility
to neutrophil phagocytosis varied markedly between the Thai
A. baumannii strains, an observation that needs further
investigation to identify the underlying causes and whether
strains that are less susceptible to neutrophil phagocytosis are
more likely to cause invasive clinical infections (as has been
shown for Streptococcus pneumoniae) (51). Although the capsule
impaired both phagocytosis and antibody access to underlying
protein antigens, our data showed improved phagocytosis of
selected heterologous strains when incubated in sera from mice
vaccinated with A. baumannii strains especially the multi strain
antisera. The effects on neutrophil phagocytosis mirrored to anFrontiers in Immunology | www.frontiersin.org 14extent the IgG binding data, although with some exceptions
(Table 3). Several studies using neutrophil depleted mice have
demonstrated the important role of neutrophils in mediating
resistance to both pneumonia (52) and bacteremia (53) following
A. baumannii infection, suggesting the in vitro data could
translate into in vivo protection against infection. Indeed, in
mice previously immunized with the three different A.
baumannii strains used to make the multi strain antisera, there
was partial reductions in target organ CFU when infected with
the heterologous AB1 strain in a bacteremia model, indicating
some protective efficacy of the anti-protein antigen response.
Protection is likely to be mediated by antibody (43), but this will
require experimental confirmation using passive transfer of




FIGURE 9 | Bacterial load in the spleen, liver, lungs and kidneys from mice following lethal challenge with heterologous AB1 isolates. (A) CD1 mice were immunized
three times with 106 CFU of either AB3879, AB1, sequentially with AB3879, AB1492-09 & AB1615-09, or PBS followed by IP infection with 6.0 x 109 CFU/mouse of
AB1 isolate in a lethal bacteremia model of infection. The bacterial burden in the (B) spleen, (C) liver, (D) lungs and (E) kidney were determined 24 hpi. Dot plots
represent individual values with lines indicating the mean and the error bars indicate standard deviations (SDs) (n = 6/group) Mann-Whitney U-test was used for
statistical analysis *p-value < 0.05, **p-value < 0.01, ns: p-value=not significant.July 2021 | Volume 12 | Article 705533
Kamuyu et al. Antibodies to Heterologous A. baumannii Strainscell mediated immunity could also contribute to the protection
observed. However, this is beyond the scope of the present work.
A. baumannii also commonly causes pneumonia and infections
on indwelling devices, urinary tract infections or soft tissue
infections and additional suitable in vivo models will be
required to comprehensively evaluate the efficacy of an
antibody therapy for the treatment of all A. baumannii
infections (54, 55). These are likely to require a degree of
immunosuppression to allow A. baumannii to establish an
infection at the target site. In summary, the in vitro data
suggest that flow cytometry measurement of IgG binding and
of neutrophil phagocytosis provide data that can correlate to in
vivo protection against bacteremia by a heterologous strain, and
hence could be used for rapid assessment of the potential
protective efficacy of a particular antisera or antibody to
A. baumannii.
Successive immunization of mice with different A. baumannii
strains may have strengthened IgG recognition of heterologous
strains compared to immunization with a single strain by
amplifying recall responses to conserved protein antigens. A
detailed characterization of the protein targets recognized by the
protective multi strain antisera is underway and will help lead to
the identification of potential monoclonal antibody targets for
enhancing neutrophil clearance of an A. baumannii infection.
Although we evaluated total IgG in this study, future work will
also evaluate IgG isotypes when characterizing protective
antibody responses to specific A. baumannii proteins, to help
guide the development of monoclonal antibodies that elicit
specific effector functions (56). However, a key challenge to
monoclonal antibody development, is the inhibitory effect of A.
baumannii capsule to both antibody binding and neutrophil
phagocytosis, as well as the genetic variation between A.
baumannii strains which makes targeting a single antigenFrontiers in Immunology | www.frontiersin.org 15unlikely to protect against all strains. An effective monoclonal
antibody therapy may have to target several A. baumannii
protein antigens to help overcome these challenges.DATA AVAILABILITY STATEMENT
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Supplementary Figure 1 | Growth inhibitory activity of unencapsulated
AB5075Dwza isolates by mouse antisera. 102 CFU of un-encapsulated AB5075Dwza
strain was incubated in triplicate with either, AB5075WT antisera (black line, solid
diamond), AB5075Dwza antisera (black line, open diamond) and sera from non-
immunized mice (grey line, solid circle) (A) or AB3879 antisera (black line, solid
square), multi strain antisera (black line, open square), and sera from non-Frontiers in Immunology | www.frontiersin.org 16immunized mice (grey line, solid circle) (B) and the OD600nm measured every 30
minutes over 24 hours.
Supplementary Figure 2 | Growth inhibitory activity on a panel of four A.
baumannii isolates by mouse antisera. 102 CFU of a panel of A. baumannii isolates
were incubated in triplicate with either AB3879 antisera (left panel) or multi strain
antisera (right panel) and the OD600nm measured every 30 minutes for 24 hours.
Sera from non-immunized mice was included as a control (open symbols). Solid
symbols represent respective anti-A. baumannii antisera. Data from two
independent experiments is shown. The five isolates are grouped by their capsule
serotype and indicated at the top of each graph in brackets. Round, square and
triangle symbols represent ST2, ST215, and ST164 MSLT types respectively.
Supplementary Figure 3 | Bacterial load in the spleen, liver and lungs from mice
following lethal challenge with homologous AB3879 strain. CD1 mice were
immunized three times with 106 CFU of the AB3879 or PBS followed by IP infection
with 2.0 x 107 CFU/mouse of the homologous AB3879 strain in a bacteremia model
of infection. The bacterial burden in the spleen, liver and lungs were determined 24
hpi. Dot plots represent individual values with lines indicating the mean and the error
bars indicate standard deviations (SDs) (n=15/group) Mann-Whitney U-test was
used for statistical analysis *p-value < 0.05, **p-value< 0.001, ***p-value < 0.0001,
ns: p-value= not significant.REFERENCES
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